Ordered and deterministic cancer genome evolution after p53 loss.

Adenocarcinoma / genetics Animals Carcinogenesis / genetics Carcinoma, Pancreatic Ductal / genetics Disease Progression Evolution, Molecular Gene Deletion Genes, p53 / genetics Genome / genetics Loss of Heterozygosity Mice Models, Genetic Pancreatic Neoplasms / genetics Tumor Suppressor Protein p53 / genetics

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
08 2022
Historique:
received: 06 06 2021
accepted: 06 07 2022
pubmed: 18 8 2022
medline: 27 8 2022
entrez: 17 8 2022
Statut: ppublish

Résumé

Although p53 inactivation promotes genomic instability

Identifiants

DOI: 10.1038/s41586-022-05082-5 PMID: 35978189 PMC: PMC9402436
pubmed: 35978189
doi: 10.1038/s41586-022-05082-5
pii: 10.1038/s41586-022-05082-5
pmc: PMC9402436
doi:

Substances chimiques

Trp53 protein, mouse 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

795-802

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087497
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA045508
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA013106
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Eischen, C. M. Genome stability requires p53. Cold Spring Harb. Perspect. Med. 6, a026096 (2016).
pubmed: 27252396 pmcid: 4888814 doi: 10.1101/cshperspect.a026096
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
doi: 10.1038/s41586-020-1969-6
Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122–128 (2020).
pubmed: 32025013 pmcid: 7054212 doi: 10.1038/s41586-019-1907-7
Kastenhuber, E. R. & Lowe, S. W. Putting p53 in context. Cell 170, 1062–1078 (2017).
pubmed: 28886379 pmcid: 5743327 doi: 10.1016/j.cell.2017.08.028
Kastan, M. B. Wild-type p53: tumors can't stand it. Cell 128, 837–840 (2007).
pubmed: 17350571 doi: 10.1016/j.cell.2007.02.022
Wahl, G. & Vafa, O. Genetic instability, oncogenes, and the p53 pathway. Cold Spring Harb. Symp. Quant. Biol. 65, 511–520 (2000).
pubmed: 12760068 doi: 10.1101/sqb.2000.65.511
Livingstone, L. R. et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70, 923–935 (1992).
pubmed: 1356076 doi: 10.1016/0092-8674(92)90243-6
Thompson, S. L. & Compton, D. A. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J. Cell Biol. 188, 369–381 (2010).
pubmed: 20123995 pmcid: 2819684 doi: 10.1083/jcb.200905057
Lane, D. P. Cancer. p53, guardian of the genome. Nature 358, 15–16 (1992).
pubmed: 1614522 doi: 10.1038/358015a0
Morris IV, J. P. et al. α-Ketoglutarate links p53 to cell fate during tumour suppression. Nature 573, 595–599 (2019).
doi: 10.1038/s41586-019-1577-5
Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661–665 (2007).
pubmed: 17251932 doi: 10.1038/nature05541
Feldser, D. M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572–575 (2010).
pubmed: 21107428 pmcid: 3003305 doi: 10.1038/nature09535
Martins, C. P., Brown-Swigart, L. & Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323–1334 (2006).
pubmed: 17182091 doi: 10.1016/j.cell.2006.12.007
Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007).
pubmed: 17251933 pmcid: 4601097 doi: 10.1038/nature05529
Donehower, L. A. et al. Integrated analysis of TP53 gene and pathway alterations in The Cancer Genome Atlas. Cell Rep. 28, 1370–1384 (2019).
pubmed: 31365877 pmcid: 7546539 doi: 10.1016/j.celrep.2019.07.001
Rausch, T. et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148, 59–71 (2012).
pubmed: 22265402 pmcid: 3332216 doi: 10.1016/j.cell.2011.12.013
Fujiwara, T. et al. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437, 1043–1047 (2005).
pubmed: 16222300 doi: 10.1038/nature04217
Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 50, 1189–1195 (2018).
pubmed: 30013179 pmcid: 6072608 doi: 10.1038/s41588-018-0165-1
Raynaud, F., Mina, M., Tavernari, D. & Ciriello, G. Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability. PLoS Genet. 14, e1007669 (2018).
pubmed: 30212491 pmcid: 6155543 doi: 10.1371/journal.pgen.1007669
Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395–399 (2012).
pubmed: 22495314 doi: 10.1038/nature10933
Cancer Genome Atlas Research Network Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185–203 (2017).
doi: 10.1016/j.ccell.2017.07.007
Rozenblum, E. et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57, 1731–1734 (1997).
pubmed: 9135016
Notta, F. et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538, 378–382 (2016).
pubmed: 27732578 pmcid: 5446075 doi: 10.1038/nature19823
Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495–501 (2015).
pubmed: 25719666 pmcid: 4523082 doi: 10.1038/nature14169
Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. 52, 231–240 (2020).
pubmed: 31932696 doi: 10.1038/s41588-019-0566-9
Litchfield, K. et al. Representative sequencing: unbiased sampling of solid tumor tissue. Cell Rep. 31, 107550 (2020).
pubmed: 32375028 doi: 10.1016/j.celrep.2020.107550
Baslan, T. & Hicks, J. Unravelling biology and shifting paradigms in cancer with single-cell sequencing. Nat. Rev. Cancer 17, 557–569 (2017).
pubmed: 28835719 doi: 10.1038/nrc.2017.58
Hingorani, S. R. et al. Trp53
pubmed: 15894267 doi: 10.1016/j.ccr.2005.04.023
Maddipati, R. & Stanger, B. Z. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov. 5, 1086–1097 (2015).
pubmed: 26209539 pmcid: 4657730 doi: 10.1158/2159-8290.CD-15-0120
Bardeesy, N. et al. Both p16
pubmed: 16585505 pmcid: 1458678 doi: 10.1073/pnas.0601273103
Saborowski, M. et al. A modular and flexible ESC-based mouse model of pancreatic cancer. Genes Dev. 28, 85–97 (2014).
pubmed: 24395249 pmcid: 3894416 doi: 10.1101/gad.232082.113
Livshits, G. et al. Arid1a restrains Kras-dependent changes in acinar cell identity. eLife 7, e35216 (2018).
pubmed: 30014851 pmcid: 6050044 doi: 10.7554/eLife.35216
Alonso-Curbelo, D. et al. A gene-environment-induced epigenetic program initiates tumorigenesis. Nature 590, 642–648 (2021).
pubmed: 33536616 pmcid: 8482641 doi: 10.1038/s41586-020-03147-x
Dow, L. E. et al. Conditional reverse tet-transactivator mouse strains for the efficient induction of TRE-regulated transgenes in mice. PLoS ONE 9, e95236 (2014).
pubmed: 24743474 pmcid: 3990578 doi: 10.1371/journal.pone.0095236
Beard, C., Hochedlinger, K., Plath, K., Wutz, A. & Jaenisch, R. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 44, 23–28 (2006).
pubmed: 16400644 doi: 10.1002/gene.20180
Morris, J. P. T., Wang, S. C. & Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 10, 683–695 (2010).
pubmed: 20814421 pmcid: 4085546 doi: 10.1038/nrc2899
Basturk, O. et al. A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am. J. Surg. Pathol. 39, 1730–1741 (2015).
pubmed: 26559377 pmcid: 4646710 doi: 10.1097/PAS.0000000000000533
Aichler, M. et al. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J. Pathol. 226, 723–734 (2012).
pubmed: 21984419 doi: 10.1002/path.3017
Mueller, S. et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature 554, 62–68 (2018).
pubmed: 29364867 pmcid: 6097607 doi: 10.1038/nature25459
Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801–1806 (2008).
pubmed: 18772397 pmcid: 2848990 doi: 10.1126/science.1164368
Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399–405 (2012).
pubmed: 23103869 pmcid: 3530898 doi: 10.1038/nature11547
Lomberk, G. et al. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nat. Commun. 9, 1978 (2018).
pubmed: 29773832 pmcid: 5958058 doi: 10.1038/s41467-018-04383-6
Huang, Y. H. et al. ID1 mediates escape from TGFβ tumor suppression in pancreatic cancer. Cancer Discov. 10, 142–157 (2020).
pubmed: 31582374 doi: 10.1158/2159-8290.CD-19-0529
Maddipati, R. et al. MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma. Cancer Discov. 12, 542–561 (2022).
pubmed: 34551968 doi: 10.1158/2159-8290.CD-20-1826
Cheng, D. T. et al. Memorial Sloan Kettering—integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251–264 (2015).
pubmed: 25801821 pmcid: 5808190 doi: 10.1016/j.jmoldx.2014.12.006
Solimini, N. L. et al. Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science 337, 104–109 (2012).
pubmed: 22628553 pmcid: 4027969 doi: 10.1126/science.1219580
Laks, E. et al. Clonal decomposition and DNA replication states defined by scaled single-cell genome sequencing. Cell 179, 1207–1221 (2019).
pubmed: 31730858 pmcid: 6912164 doi: 10.1016/j.cell.2019.10.026
Watkins, T. B. K. et al. Pervasive chromosomal instability and karyotype order in tumour evolution. Nature 587, 126–132 (2020).
pubmed: 32879494 pmcid: 7611706 doi: 10.1038/s41586-020-2698-6
Minussi, D. C. et al. Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature 592, 302–308 (2021).
pubmed: 33762732 pmcid: 8049101 doi: 10.1038/s41586-021-03357-x
List, A. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355, 1456–1465 (2006).
pubmed: 17021321 doi: 10.1056/NEJMoa061292
Kawaguchi, Y. et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat. Genet. 32, 128–134 (2002).
pubmed: 12185368 doi: 10.1038/ng959
Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243–3248 (2001).
pubmed: 11751630 pmcid: 312845 doi: 10.1101/gad.943001
Marino, S. & Vooijs, M. van Der Gulden, H., Jonkers, J. & Berns, A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 14, 994–1004 (2000).
Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847–860 (2004).
pubmed: 15607980 doi: 10.1016/j.cell.2004.11.004
Morris, J. P. T. et al. Dicer regulates differentiation and viability during mouse pancreatic cancer initiation. PLoS ONE 9, e95486 (2014).
pubmed: 24788257 pmcid: 4006805 doi: 10.1371/journal.pone.0095486
Baslan, T. et al. Genome-wide copy number analysis of single cells. Nat. Protoc. 7, 1024–1041 (2012).
pubmed: 22555242 pmcid: 5069701 doi: 10.1038/nprot.2012.039
Lee, J. et al. Synteny Portal: a web-based application portal for synteny block analysis. Nucleic Acids Res. 44, W35–W40 (2016).
pubmed: 27154270 pmcid: 4987893 doi: 10.1093/nar/gkw310
Baslan, T. et al. Optimizing sparse sequencing of single cells for highly multiplex copy number profiling. Genome Res. 25, 714–724 (2015).
pubmed: 25858951 pmcid: 4417119 doi: 10.1101/gr.188060.114
Garvin, T. et al. Interactive analysis and assessment of single-cell copy-number variations. Nat. Methods 12, 1058–1060 (2015).
pubmed: 26344043 pmcid: 4775251 doi: 10.1038/nmeth.3578
de Bourcy, C. F. et al. A quantitative comparison of single-cell whole genome amplification methods. PLoS ONE 9, e105585 (2014).
pubmed: 25136831 pmcid: 4138190 doi: 10.1371/journal.pone.0105585
Cai, X. et al. Single-cell, genome-wide sequencing identifies clonal somatic copy-number variation in the human brain. Cell Rep. 8, 1280–1289 (2014).
pubmed: 25159146 pmcid: 4272008 doi: 10.1016/j.celrep.2014.07.043
Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90–94 (2011).
pubmed: 21399628 pmcid: 4504184 doi: 10.1038/nature09807
Cleveland, W. S. Lowess—a program for smoothing scatterplots by robust locally weighted regression. Am. Stat. 35, 54 (1981).
doi: 10.2307/2683591
Venkatraman, E. S. & Olshen, A. B. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23, 657–663 (2007).
pubmed: 17234643 doi: 10.1093/bioinformatics/btl646
Krasnitz, A., Sun, G., Andrews, P. & Wigler, M. Target inference from collections of genomic intervals. Proc. Natl Acad. Sci. USA 110, E2271–E2278 (2013).
pubmed: 23744040 pmcid: 3690846 doi: 10.1073/pnas.1306909110
Chorbadjiev, L. et al. Integrated computational pipeline for single-cell genomic profiling. JCO Clin. Cancer Inform. 4, 464–471 (2020).
pubmed: 32432904 doi: 10.1200/CCI.19.00171
Alexander, J. et al. Utility of single-cell genomics in diagnostic evaluation of prostate cancer. Cancer Res. 78, 348–358 (2018).
pubmed: 29180472 doi: 10.1158/0008-5472.CAN-17-1138
Kaufmann, T. L. et al. MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution. Preprint at bioRxiv https://doi.org/10.1101/2021.02.28.433227 (2021).
Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).
pubmed: 27270079 pmcid: 5027494 doi: 10.1093/nar/gkw520
Dentro, S. C., Wedge, D. C. & Van Loo, P. Principles of reconstructing the subclonal architecture of cancers. Cold Spring Harb. Perspect. Med. 7, a026625 (2017).
pubmed: 28270531 pmcid: 5538405 doi: 10.1101/cshperspect.a026625
McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra254 (2015).
doi: 10.1126/scitranslmed.aaa1408

Auteurs

Timour Baslan (T)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

John P Morris (JP)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Zhen Zhao (Z)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Jose Reyes (J)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Howard Hughes Medical Institute, Chevy Chase, MD, USA.

Yu-Jui Ho (YJ)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Kaloyan M Tsanov (KM)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Jonathan Bermeo (J)

Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0002-9553-9222

Sha Tian (S)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Sean Zhang (S)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Gokce Askan (G)

Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Aslihan Yavas (A)

Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0002-8408-3063

Nicolas Lecomte (N)

Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Amanda Erakky (A)

Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Anna M Varghese (AM)

Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Amy Zhang (A)

PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

Jude Kendall (J)

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

Elena Ghiban (E)

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

Lubomir Chorbadjiev (L)

Technical School of Electronic Systems, Technical University of Sofia, Sofia, Bulgaria.

Jie Wu (J)

Phillips Research North America, Oncology Informatics and Genomics, Cambridge, MA, USA.
ORCID: 0000-0002-0989-8115

Nevenka Dimitrova (N)

Phillips Research North America, Oncology Informatics and Genomics, Cambridge, MA, USA.

Kalyani Chadalavada (K)

Molecular Cytogenetics Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Gouri J Nanjangud (GJ)

Molecular Cytogenetics Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0002-8547-1957

Chaitanya Bandlamudi (C)

Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Yixiao Gong (Y)

Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Mark T A Donoghue (MTA)

Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Nicholas D Socci (ND)

Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Alex Krasnitz (A)

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

Faiyaz Notta (F)

PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

Steve D Leach (SD)

Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dartmouth Cancer Center, Hanover, NH, USA.
ORCID: 0000-0002-2689-1871

Christine A Iacobuzio-Donahue (CA)

Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0002-4672-3023

Scott W Lowe (SW)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lowes@mskcc.org.
Howard Hughes Medical Institute, Chevy Chase, MD, USA. lowes@mskcc.org.
ORCID: 0000-0002-5284-9650

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › Ordered and deterministic cancer genome...
questionsmedicales.fr › Eucaryotes › Animaux › Ordered and deterministic cancer genome...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Carcinogenèse › Ordered and deterministic cancer genome...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › Carcinome du canal pancréatique › Ordered and deterministic cancer genome...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Ordered and deterministic cancer genome...
questionsmedicales.fr › Phénomènes biologiques › Évolution biologique › Évolution moléculaire › Ordered and deterministic cancer genome...
questionsmedicales.fr › Phénomènes génétiques › Mutagenèse › Délétion de séquence › Délétion de gène › Ordered and deterministic cancer genome...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Gènes suppresseurs de tumeur › Gènes p53 › Ordered and deterministic cancer genome...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Ordered and deterministic cancer genome...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Déséquilibre allélique › Perte d'hétérozygotie › Ordered and deterministic cancer genome...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Ordered and deterministic cancer genome...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles génétiques › Ordered and deterministic cancer genome...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › Ordered and deterministic cancer genome...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › Ordered and deterministic cancer genome...